Guangzhou LBP Medicine Science & Technology Co Ltd (688393) — Net Asset Quality Index
Guangzhou LBP Medicine Science & Technology Co Ltd (688393) has a Net Asset Quality Index of 91.4% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.31 Billion minus total liabilities of CN¥113.31 Million yields net assets of CN¥1.20 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Guangzhou LBP Medicine Science & Technol debt and liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Guangzhou LBP Medicine Science & Technology Co Ltd Net Asset Quality Index Over Time (2011–2024)
This chart shows how Guangzhou LBP Medicine Science & Technology Co Ltd's Net Asset Quality Index has evolved across 12 annual periods from 2011 to 2024. As of September 2025, the index stands at 91.4%, representing net assets of CN¥1.20 Billion against total assets of CN¥1.31 Billion CNY. For live market cap and overall valuation, see Guangzhou LBP Medicine Science & Technol market capitalisation.
Annual Net Asset Quality Index for Guangzhou LBP Medicine Science & Technology Co Ltd (2011–2024)
The table below presents the year-by-year Net Asset Quality Index for Guangzhou LBP Medicine Science & Technology Co Ltd from 2011 to 2024, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See net assets of Guangzhou LBP Medicine Science & Technol for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 90.4% | CN¥1.23 Billion | CN¥1.36 Billion | CN¥130.99 Million | ▲ +1.9 pp |
| 2023 | 88.5% | CN¥1.24 Billion | CN¥1.40 Billion | CN¥161.63 Million | ▲ +0.7 pp |
| 2022 | 87.8% | CN¥1.22 Billion | CN¥1.39 Billion | CN¥170.45 Million | ▼ -0.8 pp |
| 2021 | 88.6% | CN¥1.21 Billion | CN¥1.37 Billion | CN¥155.96 Million | ▼ -1.8 pp |
| 2020 | 90.4% | CN¥1.17 Billion | CN¥1.29 Billion | CN¥124.67 Million | ▲ +7.7 pp |
| 2019 | 82.7% | CN¥444.63 Million | CN¥537.96 Million | CN¥93.33 Million | ▲ +1.0 pp |
| 2018 | 81.7% | CN¥389.32 Million | CN¥476.56 Million | CN¥87.25 Million | ▼ -2.3 pp |
| 2017 | 84.0% | CN¥346.28 Million | CN¥412.06 Million | CN¥65.78 Million | ▼ -5.9 pp |
| 2016 | 89.9% | CN¥320.94 Million | CN¥357.02 Million | CN¥36.08 Million | ▲ +6.3 pp |
| 2013 | 83.6% | CN¥215.00 Million | CN¥257.13 Million | CN¥42.13 Million | ▼ -6.7 pp |
| 2012 | 90.3% | CN¥173.32 Million | CN¥191.92 Million | CN¥18.60 Million | ▲ +47.1 pp |
| 2011 | 43.2% | CN¥48.09 Million | CN¥111.40 Million | CN¥63.31 Million | — |